#9 Clinical Trend: Zydelig
Idelalisib (Zydelig) was recently approved by the FDA for treatment of chronic lymphocytic leukemia (CLL). It was given breakthrough therapy designation and joins obinutuzumab, ofatumumab, and ibrutinib as recently approved medications for the treatment of CLL. Idelalisib was specifically approved for use in combination with rituximab in patients with comorbidities that would require treatment with rituximab alone.
For more in-depth clinical information, see Chronic Lymphocytic Leukemia Medication.
Medscape © 2014
Cite this: Top 10 Trends in Medicine, August 2014 - Medscape - Aug 26, 2014.